497 related articles for article (PubMed ID: 8626358)
21. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms.
Ciraulo DA; Knapp C; Rotrosen J; Sarid-Segal O; Ciraulo AM; LoCastro J; Greenblatt DJ; Leiderman D
Addiction; 2005 Mar; 100 Suppl 1():23-31. PubMed ID: 15730347
[TBL] [Abstract][Full Text] [Related]
22. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders.
Baca E; Garcia-Garcia M; Porras-Chavarino A
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):57-65. PubMed ID: 14687858
[TBL] [Abstract][Full Text] [Related]
23. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.
Feighner JP; Pambakian R; Fowler RC; Boyer WF; D'Amico MF
Psychopharmacol Bull; 1989; 25(2):219-21. PubMed ID: 2690165
[TBL] [Abstract][Full Text] [Related]
24. A double-blind comparison of paroxetine, imipramine, and placebo in major depression.
Shrivastava RK; Shrivastava SH; Overweg N; Blumhardt CL
J Clin Psychiatry; 1992 Feb; 53 Suppl():48-51. PubMed ID: 1531825
[TBL] [Abstract][Full Text] [Related]
25. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
Fabre LF
J Clin Psychiatry; 1992 Feb; 53 Suppl():40-3. PubMed ID: 1531823
[TBL] [Abstract][Full Text] [Related]
26. Nefazodone and imipramine in major depression: a placebo-controlled trial.
Rickels K; Schweizer E; Clary C; Fox I; Weise C
Br J Psychiatry; 1994 Jun; 164(6):802-5. PubMed ID: 7952987
[TBL] [Abstract][Full Text] [Related]
27. Long-term treatment of depression with nefazodone.
Anton SF; Robinson DS; Roberts DL; Kensler TT; English PA; Archibald DG
Psychopharmacol Bull; 1994; 30(2):165-9. PubMed ID: 7831450
[TBL] [Abstract][Full Text] [Related]
28. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
Feiger AD
Psychopharmacol Bull; 1996; 32(4):659-65. PubMed ID: 8993088
[TBL] [Abstract][Full Text] [Related]
29. Paroxetine in the treatment of depression: a comparison with imipramine and placebo.
Feighner JP; Boyer WF
J Clin Psychiatry; 1992 Feb; 53 Suppl():44-7. PubMed ID: 1531824
[TBL] [Abstract][Full Text] [Related]
30. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
Simon JS; Aguiar LM; Kunz NR; Lei D
J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
[TBL] [Abstract][Full Text] [Related]
31. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity.
Sajatovic M; DiGiovanni S; Fuller M; Belton J; DeVega E; Marqua S; Liebling D
Clin Ther; 1999 Apr; 21(4):733-40. PubMed ID: 10363738
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression.
Shrivastava RK; Cohn C; Crowder J; Davidson J; Dunner D; Feighner J; Kiev A; Patrick R
J Clin Psychopharmacol; 1994 Oct; 14(5):322-9. PubMed ID: 7806687
[TBL] [Abstract][Full Text] [Related]
33. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring.
Gründer G; Wetzel H; Schlösser R; Benkert O
Pharmacopsychiatry; 1996 Mar; 29(2):72-8. PubMed ID: 8741025
[TBL] [Abstract][Full Text] [Related]
34. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
Dominguez RA; Goldstein BJ; Jacobson AF; Steinbook RM
J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993
[TBL] [Abstract][Full Text] [Related]
35. Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III).
Versiani M; Nardi AE; Mundim FD; Alves AB
J Neural Transm Suppl; 1989; 28():65-75. PubMed ID: 2794994
[TBL] [Abstract][Full Text] [Related]
36. A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients.
Cohn JB; Varga L; Lyford A
J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):68-72. PubMed ID: 6370980
[TBL] [Abstract][Full Text] [Related]
37. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
[TBL] [Abstract][Full Text] [Related]
38. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
Gillin JC; Rapaport M; Erman MK; Winokur A; Albala BJ
J Clin Psychiatry; 1997 May; 58(5):185-92. PubMed ID: 9184611
[TBL] [Abstract][Full Text] [Related]
39. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone.
Elliott AJ; Russo J; Bergam K; Claypoole K; Uldall KK; Roy-Byrne PP
J Clin Psychiatry; 1999 Apr; 60(4):226-31. PubMed ID: 10221282
[TBL] [Abstract][Full Text] [Related]
40. A pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression.
Mercier MA; Stewart JW; Quitkin FM
J Clin Psychiatry; 1992 May; 53(5):166-70. PubMed ID: 1592844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
